Molecular docking and toxicity analysis of ribosome-inactivating protein and natural chemical compounds as promising antiretroviral candidates against HIV-1
DOI:
https://doi.org/10.46542/pe.2024.246.9098Keywords:
CD4, HIV-1 reverse transcriptase, Ibalizumab, Molecular docking, ZidovudineAbstract
Background: HIV (human immunodeficiency virus) uses HIV-1 reverse transcriptase as the receptor to convert RNA into viral DNA. In addition, the CD4 receptor is also used by the virus to enter CD4+ T cells and subsequently replicate.
Objective: To screen several proteins in Indonesian plants for the potential to bind to the CD4 receptor.
Method: Molecular docking was carried out on Cluspro 2.0 specifically for protein to protein and MOE for protein to ligand.
Results: The protein ligands were Cinnamomin III, Agglutinin, PAP, PAP-S, Momordin I, MAP30, Beta-luffin, Luffaculin I, Cucurmosin, DAP, Dianthin-30, Bouganin, Maize, Ricin, Abrin, Balsamin, and the bond energy values (Joules/kg.mol) were -602.8, -973.5, -511.3, -439.1, -532.2, -661.9, -487.0, -472.8, -530.9, -413.6, 444.1, -504.5, -617.2, -855.6, -883.9, -558.6, respectively. The best binding energy with CD4 was selected to identify the compound's molecule. These compounds were abrusin, abrusogenin, eicosadienoic acid, heneicosane, precatorine, and trigonelline, and the bond energy values (Joules/kg.mol) were -19.2158, -16.7057, -15.5155, -13.9632, -15.6119, and -9.2620, respectively. The toxicity test of abrusin was carried out against 18 targets, and two targets showed toxic activities.
Conclusion: The content of RIP and natural chemical compounds in Abrus precatorius seeds make them the best candidate for antiretroviral therapy against HIV-1.
References
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., The International Natural Product Sciences Taskforce, & Supurans, C. T. (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews Drug Discovery, 20, 200–216. https://doi.org/10.1038/s41573-020-00114-z
Beccari, M. V, Mogle, B. T., Sidman, E. F., Mastro, K. A., Asiago-Reddy, E., & Kufel, W. D. (2019). Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection. https://doi.org/10.1128/AAC
Zerdan, B. M., Moussa, S., Atoui, A., & Assi, A. I. (2021). Mechanisms of immunotoxicity: Stressors and evaluators. International Journal of Molecular Sciences, 22(15), 8242. https://doi.org/10.3390/ijms22158242
Citores, L., Iglesias, R., & Ferreras, J. M. (2021) Antiviral activity of ribosome-inactivating proteins. Toxins, 13, 2. https://doi.org/10.3390/toxins13020080
Das, K., & Arnold, E. (2013). HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Current opinion in virology, 3.2(2013), 111–118. https://doi.org/10.1016/j.coviro.2013.03.012
Yogita, G., Anderson, P. L., Sangkuhl, K., Lamba, J., Altman, R. B., & Klein, T. E. (2012). PharmGKB summary. Pharmacogenetics and Genomics, 22(12), 891–894. https://www.doi.org/10.1097/fpc.0b013e32835879a8
Hevener, K. E., Zhao, W., Ball, D. M., Babaoglu, K., Qi, J., White, S. W., & Lee, R. E. (2009). Validation of molecular docking programs for virtual screening against dihydropteroate synthase. Journal of Chemical Information and Modeling, 49.2(2009), 444–460. https://doi.org/10.1021/ci800293n
Kozakov, D., Hall, D. R., Xia, B., Porter, K. A., Padhorny, D., Yueh, C., Beglov, D., & Vadja, S. (2017). The ClusPro web server for protein-protein docking. Nat Protoc, 12(2), 255–78. https://doi.org/10.1038/nprot.2016.169
Laskowski, R. A., Jabłońska, J., Pravda L., Vařekova, R. S., & Thornton, J. M. (2018). PDBsum: Structural summaries of PDB entries. Protein Sci, 27.1(2018), 129–34. https://doi.org/10.1002/pro.3289
Limmatvapirat, C., Sirisopanaporn, S., & Kittakoop, P. Antitubercular and antiplasmodial constituents of Abrus precatorius. Planta Medica, 70.3(2004), 276–278. https://doi.org/10.1055/s-2004-818924
Ruswanto. Molecular docking of four isonicotinohydrazide derivatives on Mycobacterium tuberculosis Enoyl-Acyl Carrier Protein Reductase (InhA). Bakti Tunas Husada Health Journal, 13.1(2015). http://dx.doi.org/10.36465/jkbth.v13i1.25
Schrodinger LLC. The PyMOL Molecular Graphics System, Version 1.8. 2015.
Seckler, J. M., Howard, K. J., Barkley, M. D., & Wintrode, P. L. (2009). Solution structural dynamics of HIV-1 reverse transcriptase heterodimer. Biochemistry, 48(32), 7646–7655. https://doi.org/10.1021/bi900790x
Sedov, I. A., Stolov, M. A., & Solomonov, B. N. (2011). Solvophobic effects and relationships between the Gibbs energy and enthalpy for the solvation process. Journal of Physical Organic Chemistry, 24.11(2011), 1088–1094. https://doi.org/10.1002/poc.1859
Shivanna, B., Chun, C., & Bhagavatula, M. (2022). The Aryl Hydrocarbon Receptor (AHR): A novel therapeutic target for pulmonary diseases? International Journal of Molecular Sciences, 23.3(2022), 1516. https://doi.org/10.3390/ijms23031516
Surendranath, K., & Karande, A. A. (2008). A neutralizing antibody to the A chain of abrin inhibits abrin toxicity both in vitro and in vivo. Clinical and Vaccine Immunology, 15.5(2008), 737–743. https://doi.org/10.1128/CVI.00254-07
Victoria, A., & Mrsc, O. (2020). Molecular docking study of bioactive compounds of Abrus Precatorius as potential drug Inhibitors Against Covid-19 Protein 6lu7. Kala Sarovar, 23(2), 18‒32. https://doi.org/10.13140/RG.2.2.17419.72483
Walsh, M. J., Jennifer, E. D., & Guillaume, M. H. (2013). Ribosome-inactivating proteins: Potent poisons and molecular tools. Virulence, 4.8(2013), 774–784. https://doi.org/10.4161/viru.2639
